No data corroborate the hypothesis that the GLP1-RAs may revert clinically established liver fibrosis [33,34], and further studies are needed to better understand how these drugs may have a therapeutic rationale for the treatment of MASH and metabolically related liver fibrosis and cirrhosis [35]. This evidence concerns the gene GCG and Hepatic fibrosis.